Journal of Clinical Oncology, Vol 16, 86-92, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

M Lopez, P Vici, K Di Lauro, F Conti, G Paoletti, A Ferraironi, R Sciuto, D Giannarelli and CL Maini
Department of Medical Oncology II, Regina Elena Institute for Cancer Research, Rome, Italy.

PURPOSE: We conducted a randomized trial to evaluate primarily the cardioprotective effect of dexrazoxane (DEX) in patients with advanced breast cancer and soft tissue sarcomas (STS) treated with high-dose epirubicin (EPI). We wished also to determine the value of radioimmunoscintigraphy (RIS) in the assessment of anthracycline cardiotoxicity. PATIENTS AND METHODS: Patients with breast cancer (n = 95) or STS (n = 34) received EPI 160 mg/m2 by intravenous (I.V.) bolus every 3 weeks with or without DEX 1,000 mg/m2 I.V. Cardiac monitoring included multigated radionuclide (MUGA) scans with determination of resting left ventricular ejection fraction (LVEF), and RIS with indium 111 antimyosin monoclonal antibodies. RESULTS: In either disease, antitumor response rates, time to progression, and survival did not significantly differ between the two arms. There was little difference in noncardiac toxicity for the two treatment groups. All methods of cardiac evaluation clearly documented the cardioprotective effect of DEX. Four patients developed congestive heart failure (CHF), all in the EPI arm. The decrease in LVEF from baseline was significantly greater in the control group. An abnormal antimyosin uptake was observed early in both arms and progressively increased during treatment. However, this increase was significantly higher in the EPI group (P = .004). CONCLUSION: DEX significantly protects against the development of cardiotoxicity when high single doses of EPI are used. Apparently, there was no evidence of an adverse impact of DEX on antitumor activity. Although RIS is a sensitive technique in detecting anthracycline cardiac damage, its specificity is low and it cannot be considered a primary test for guiding anthracycline treatment.

This article has been cited by other articles:

				E. V. Barry, L. M. Vrooman, S. E. Dahlberg, D. S. Neuberg, B. L. Asselin, U. H. Athale, L. A. Clavell, E. C. Larsen, A. Moghrabi, Y. Samson, et al. Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane J. Clin. Oncol., March 1, 2008; 26(7): 1106 - 1111. [Abstract] [Full Text] [PDF]

				E. V. Barry, S. E. Lipshultz, and S. E. Sallan Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention ASCO Educational Book, January 1, 2008; 2008(1): 448 - 453. [Abstract] [Full Text] [PDF]

				S. K. Bjelogrlic, J. Radic, S. Radulovic, M. Jokanovic, and V. Jovic Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy In Vivo Experimental Biology and Medicine, December 1, 2007; 232(11): 1414 - 1424. [Abstract] [Full Text] [PDF]

				T. L'Ecuyer, S. Sanjeev, R. Thomas, R. Novak, L. Das, W. Campbell, and R. V. Heide DNA damage is an early event in doxorubicin-induced cardiac myocyte death Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1273 - H1280. [Abstract] [Full Text] [PDF]

				M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport, V. Stahalova, and On behalf of the Dexrazoxane Study Group Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy Ann. Onc., April 1, 2006; 17(4): 614 - 622. [Abstract] [Full Text] [PDF]

				R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]

				Committee Members, F. J. Klocke, M. G. Baird, B. H. Lorell, T. M. Bateman, J. V. Messer, D. S. Berman, P. T. O'Gara, B. A. Carabello, R. O. Russell Jr, et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1318 - 1333. [Full Text] [PDF]

				F. J. Klocke, M. G. Baird, B. H. Lorell, T. M. Bateman, J. V. Messer, D. S. Berman, P. T. O'Gara, B. A. Carabello, R. O. Russell Jr, M. D. Cerqueira, et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) Circulation, September 16, 2003; 108(11): 1404 - 1418. [Full Text] [PDF]

				L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903. [Full Text] [PDF]

				M. Lopez, P. Vici, L. Di Lauro, and S. Carpano Increasing Single Epirubicin Doses in Advanced Soft Tissue Sarcomas J. Clin. Oncol., March 1, 2002; 20(5): 1329 - 1334. [Abstract] [Full Text] [PDF]

				M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]

				L.C.M. Kremer, M.M.C. Tiel-van Buul, M.C. Ubbink, M. Offringa, J. Ottenkamp, R. V. Olmos, and P.A. Voute Indium-111-Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children J. Clin. Oncol., April 1, 1999; 17(4): 1208 - 1208. [Abstract] [Full Text] [PDF]